Nebenwirkungen · Casgevy
Casgevy 4 - 13 × 106 cells/mL dispersion for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-149346 · Präparat HOS-100036
Respiratory, thoracic and Acute respiratory distress syndrome, idiopathic mediastinal disorders pneumonia syndrome †, epistaxis † Skin and subcutaneous tissue Rash †, §, petechiae † disorders General disorders and Chills †, pyrexia † administration site conditions Injury, poisoning and Delayed engraftment †, infusion related reactions # procedural complications * Frequency is based on the highest incidence from study 111 in patients with TDT or from study 121 in patients with SCD. † At least one event was also attributed to busulfan myeloablative conditioning. ‡ Lymphopenia included CD4 lymphocytes decreased and lymphocyte count decreased. § Rash included dermatitis. # Infusion related reactions included chills, sinus tachycardia, and tachycardia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T14:50:00Z · SHA-256 88371a72474d6cc8476d82edcf74bc7f8b779e890b5a4d457f22edba3fd2067e · Passage 10970bd7c57fdbf1da1f35dc2b26ffd24ad518b9095dec87d444bca28874e04e · Zeichen 12654–13742 im Abschnitt